Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John H Strickler
Academic and Community Cancer Research United
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
- Uc San Diego Moores Cancer Center
La Jolla, California, United States
- Cedars Sinai Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
- Medstar Washington Hospital Center
Washington D.C., District of Columbia, United States
- Mayo Clinic in Florida
Jacksonville, Florida, United States
- Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- Brigham and Women'S Hospital
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
- M D Anderson Cancer Center
Houston, Texas, United States
- Aurora Cancer Care-Milwaukee West
Wauwatosa, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Apr 2020
- Primary completion
- 1 Dec 2023
- Completion
- 7 Oct 2024
- Last update posted
- 21 May 2024
- Registered enrollment
- 12
- Registry id
- NCT03992456
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.